When Does Direct Compression of Liposomal Zinc Exceed a Safe Shear Threshold?

Direct compression of a spray-dried liposomal zinc API on high-speed rotary tablet presses is constrained by the mechanical fragility of the phospholipid bilayer and the low bulk density of the spray-dried intermediate. The API is typically co-spray-dried with trehalose, mannitol, or maltodextrin as a lyoprotectant, yielding a free-flowing powder with bulk density in the range of 0.35 g/cm³ to 0.55 g/cm³ and tapped density in the range of 0.55 g/cm³ to 0.75 g/cm³; these values produce Carr index values between 25 and 35, which necessitates glidant addition prior to compression. A formulation that maintains lipid bilayer integrity on an IMA Comprima 300 or Fette 2090i press includes microcrystalline cellulose at 35% w/w to 45% w/w, mannitol at 20% w/w to 30% w/w, crospovidone at 2% w/w to 4% w/w, colloidal silicon dioxide at 0.5% w/w to 1.0% w/w, sodium stearyl fumarate at 0.5% w/w to 1.5% w/w, and liposomal zinc API equivalent to 15 mg or 30 mg of elemental zinc per tablet. Lubrication is performed as a final 3-minute tumble blend after a 15-minute initial blend of the non-lubricated components, because extended lubrication above 5 minutes at 24 rpm increases the disintegration time of the compressed tablet beyond 15 minutes when tested by USP <701>. Compression force is maintained between 8 kN and 15 kN for a 700 mg oblong tablet with a punch tip area of approximately 1.2 cm², corresponding to compaction pressure of 67 MPa to 125 MPa; above 150 MPa, the lipid bilayer of a non-PEGylated zinc liposome may undergo irreversible fusion or release of ionic zinc, although published quantitative rupture thresholds for this specific API configuration are limited. The powder blend must be transferred to the hopper at ambient relative humidity below 40% and at 18°C to 22°C, because phospholipid powders absorb surface moisture above 40% RH and generate die-wall filming on the lower punch face. Tablet hardness is monitored at 70 N to 110 N, friability is controlled to ≤0.8% by USP <1216>, and content uniformity is determined by USP <905> using 10 dosage units with an acceptance value not exceeding 15.0. Dissolution testing of the finished tablet is performed in 900 mL of 0.1 N hydrochloric acid at 37°C ± 0.5°C using USP <711> apparatus 2 at 50 rpm to 75 rpm; the dissolution specification for liposomal zinc is not compendial and must be justified by the sponsor through a discriminatory method that distinguishes free zinc from encapsulated zinc using equilibrium dialysis or ultrafiltration. Tablets are film-coated with a 3% w/w to 4% w/w aqueous ethylcellulose or polyvinyl alcohol-based coating in a pan coater with inlet air temperature set at 55°C to 65°C and product bed temperature held below 40°C to avoid phase transition of the phospholipids. Terminal tablets are packaged in 60 cm³ HDPE bottles with 1 g silica gel canisters and induction-sealed closures; under accelerated conditions of 40°C ± 2°C and 75% RH ± 5% RH, the package configuration must maintain headspace moisture below 30% RH and maintain elemental zinc assay within 95.0% to 105.0% of label claim for 6 months.

Capsule filling of liposomal zinc API is approached as a low-shear, moisture-controlled operation rather than as a conventional dry powder fill because the phospholipid envelope of the spray-dried intermediate carries a measurable zeta potential and can become electrostatically charged during transfer through stainless steel dosing nozzles. In a Zanasi 12E or Bosch GKF 1500 capsule filler, the dosator pin height is set between 5 mm and 12 mm and compression station dwell is kept below 80 ms; higher dwell or pin penetration into the powder bed compacts the low-density liposomal powder inside the dosator and produces a plug that retains capsule-shaped cracks after ejection. The premix is manufactured in a 200 L bin blender at 12 rpm for 20 minutes with a fill volume of 60% to 70%, using mannitol as the primary diluent at 45% w/w to 60% w/w, microcrystalline cellulose at 20% w/w to 30% w/w, sodium starch glycolate at 2% w/w to 4% w/w, colloidal silicon dioxide at 0.5% w/w to 1.0% w/w, magnesium stearate at 0.25% w/w to 0.5% w/w, and liposomal zinc API equivalent to 15 mg, 25 mg, or 50 mg elemental zinc per HPMC capsule. The material is filled into size 00 or size 1 HPMC capsules at a target fill weight of 400 mg to 650 mg; empty capsule shells are conditioned at 35% RH to 45% RH for 24 hours before filling because brittle fracture of HPMC shells below 30% RH causes split bodies on ejection. The filled capsules are dedusted and metal checked, then sealed in aluminum/PVC cold-form blisters with a desiccant pouch. Fill weight uniformity is verified every 30 minutes by taking 20 capsules from each dosing station and comparing individual weights to the moving average; the production acceptance criterion is an individual fill weight deviation not greater than ±5% from target and an RSD not greater than 3.0%, while finished product content uniformity is confirmed by USP <905>. Because the liposomal zinc powder is sensitive to hydrolytic degradation of phosphatidylcholine, the blend is held in drums fitted with airtight lids containing activated molecular sieve sachets, and the maximum hold time between blending and encapsulation is 4 hours at 25°C ± 2°C and 35% RH ± 5% RH. The terminal capsule product is tested for zinc assay by ICP-OES according to USP <730>, disintegration by USP <701> with a 6-capsule limit of not more than 15 minutes in 900 mL water at 37°C ± 2°C, and dissolution by USP <711> apparatus 2 at 50 rpm in 900 mL 0.1 N hydrochloric acid with sampling at 5, 10, 15, 30, and 45 minutes. Published data for the in vivo absorption of liposomal zinc delivered in HPMC capsules relative to zinc sulfate tablets is limited; therefore, the dissolution method is expected to be qualified as a quality control release test rather than as an in vivo predictive tool.

Dry Granulation Pathways and Roller Compactor Parameters for Sachet Formats

Roller compaction is the preferred size-enlargement route for liposomal zinc API in granule and stick-pack formats when the direct blend has insufficient flow for high-speed sachet dosing or when the API load exceeds 30% w/w of the finished powder. Wet granulation is avoided because aqueous binder solutions plasticize the phospholipid bilayer and can induce vesicle fusion, while high-shear granulation introduces thermal energy and shear rates that reduce encapsulation efficiency; dry granulation confines the API to a short, controlled pressure dwell. On a Gerteis Mini-Pactor operating with smooth rolls, the ribbon is produced at a roll force of 4 kN/cm to 8 kN/cm, roll speed of 2 rpm to 5 rpm, gap width of 2.0 mm to 3.0 mm, and roll surface temperature held below 30°C by closed-loop cooling. The pre-compacted blend consists of liposomal zinc API equivalent to 20 mg or 30 mg elemental zinc per sachet, mannitol at 40% w/w to 55% w/w, microcrystalline cellulose at 25% w/w to 35% w/w, crospovidone at 3% w/w to 6% w/w, colloidal silicon dioxide at 0.5% w/w to 1.0% w/w, and sodium stearyl fumarate at 1.0% w/w to 2.0% w/w. The granulator is fitted with a 0.8 mm to 1.25 mm rasp screen at 50 rpm; fine fraction below 150 µm is recycled to the compactor at a ratio not exceeding 30% of the fresh feed, because recycled fines are depleted in lipid-coated zinc and increase segregation potential in subsequent sachet dosing. The resulting granules have a bulk density of 0.50 g/cm³ to 0.70 g/cm³, a Hausner ratio below 1.25, and a flow through a 15 mm orifice of not less than 10 g/s by USP <1174>. Sachet filling is performed on a vertical form-fill-seal machine with an auger filler calibrated for 1.0 g to 2.0 g stick-pack doses; fill weight is checked every 10 minutes with a 20-sachet moving average and controlled to ±3% of target. The final powder is tested for loss on drying at 60°C for 15 minutes by USP <731>, with a limit of ≤2.0%, and for moisture sorption by Karl Fischer titration with a limit of ≤1.5% water. Dissolution of the granule formulation is run in USP <711> apparatus 2 at 75 rpm in 900 mL 0.1 N hydrochloric acid; because the liposomal zinc is embedded in a mannitol-based matrix, complete release of elemental zinc is typically achieved within 15 minutes if the granules are not overcompacted, but a product-specific limit is set from development data. The terminal sachet laminate is a 12 µm polyester / 9 µm aluminum foil / 50 µm polyethylene structure sealed at 140°C to 160°C; oxygen transmission rate is below 0.1 cm³/m²/day/atm and moisture vapor transmission rate is below 0.05 g/m²/day at 23°C and 85% RH, which protects unsaturated phospholipids from oxidative degradation. A sachet product intended as an oral prescription or supplement in the European market must comply with the manufacturing provisions of EU GMP Part II for active substances when the granule is classified as an intermediate and with the labelling provisions of Regulation (EU) No 1169/2011 for nutrient declarations.

Intravenous and intramuscular use of liposomal zinc API is governed by a different set of particle size, sterility, and bacterial endotoxin controls than oral solid-dosage processing because the product bypasses the gastrointestinal epithelium and is introduced directly into the vascular compartment. A liposomal zinc injectable is typically manufactured as a sterile aqueous dispersion in which zinc sulfate or zinc gluconate is encapsulated in the internal aqueous phase of a small unilamellar vesicle composed of hydrogenated soy phosphatidylcholine and cholesterol; after remote loading or passive entrapment, unencapsulated zinc is removed by tangential flow filtration or dialysis against a 10 mM histidine or phosphate buffer at pH 6.0 to 7.5. The particle size distribution following high-pressure homogenization is controlled to a D50 of 80 nm to 150 nm and a D90 not exceeding 200 nm by dynamic light scattering according to ISO 22412:2017; this D90 ceiling is operationally critical because it permits terminal sterilization by filtration through a 0.22 µm polyethersulfone membrane, whereas liposomes with D90 above 200 nm cannot be sterile-filtered and require aseptic processing under EU GMP Annex 1 Grade A conditions with a Grade B background. Sterile filtration is performed at 20°C to 25°C under a differential pressure of 0.5 bar to 1.0 bar, and the filter is integrity-tested before and after use by the forward-flow method of ASTM F838-20. The filtered intermediate is filled into 5 mL or 10 mL Type I glass vials under nitrogen overlay, stoppered with bromobutyl closures, and stored at 2°C to 8°C; terminal steam sterilization at 121°C is not acceptable because phospholipid hydrolysis and zinc leakage increase sharply above the gel-to-liquid crystalline phase transition temperature of the selected phospholipid, which is between 50°C and 55°C for hydrogenated soy phosphatidylcholine. Critical quality attributes for release include bacterial endotoxins by USP <85> with a product-specific limit calculated from the maximum bolus dose, sterility by USP <71>, subvisible particulate matter by USP <787> using the light obscuration method, osmolality by USP <785> adjusted to 280 mOsm/kg to 320 mOsm/kg before infusion with 0.9% sodium chloride injection or 5% dextrose injection, and pH by USP <791> maintained within the product specification derived from stability. Because lipid nanoparticles are known to interfere with light obscuration counts, the subvisible particle result is corroborated by micro-flow imaging or dynamic imaging particle analysis when the product shows counts above 250 particles per mL at ≥10 µm in the finished vial; this orthogonal approach reduces the risk of false rejection caused by vesicle aggregates rather than glass delamination or proteinaceous particles. Zinc concentration is determined by ICP-OES according to USP <730> after acid digestion, and encapsulation efficiency is calculated as the ratio of zinc retained inside the liposome after ultrafiltration to total zinc, with a development-stage acceptance criterion typically not less than 70%; published limits for liposomal zinc injection are product-specific and not harmonized across compendia. The manufacturing facility must operate under 21 CFR 211.42 for environmental controls, 21 CFR 211.113(b) for aseptic processing when filtration is not possible, and 21 CFR 211.165 for final release testing; raw phospholipids must comply with ICH Q3D elemental impurity limits for residual metals from hydrogenation catalysts, and the finished drug product must meet 21 CFR 211.167 for sterility and 21 CFR 211.194 for laboratory records. Table 1 lists the release-test matrix for a liposomal zinc injection intended for intravenous infusion.

When Liposomal Zinc Is Dispersed into Aqueous Oral Vehicles for Pediatric Administration

Extemporaneous compounding of liposomal zinc powder into an aqueous oral suspension for pediatric and geriatric patients is governed by the ionic strength and osmolality of the vehicle, because a liposomal dispersion in plain purified water can undergo osmotic swelling of the vesicles and leakage of encapsulated zinc within 24 hours. The compounding pharmacy or hospital pharmacy operation first prepares a vehicle containing 0.9% w/w sodium chloride or an isotonic phosphate buffer at pH 6.5 to 7.4, plus 20% w/w sorbitol or 10% w/w glycerol as a sweetening and density-modifying agent, and 0.1% w/w potassium sorbate as a preservative. Liposomal zinc API equivalent to 15 mg elemental zinc per 5 mL is dispersed into the vehicle using a propeller mixer at 300 rpm to 500 rpm for 5 minutes; high-shear homogenization above 3,000 rpm is prohibited because it ruptures the phospholipid bilayer, reduces encapsulation efficiency, and produces free zinc ions that may cause metallic taste and local irritation. The suspension is then passed through a 180 µm stainless steel screen to remove aggregates without reducing the liposome content. The resulting oral suspension has a pH of 6.5 to 7.5, an osmolality of 250 mOsm/kg to 350 mOsm/kg, and a viscosity of 20 mPa·s to 50 mPa·s when measured at 25°C with a Brookfield viscometer spindle LV3 at 30 rpm. The product is dispensed in a 30 mL or 100 mL amber Type III glass bottle with a child-resistant closure and stored at 2°C to 8°C; published stability data for this specific configuration is limited, but a beyond-use date of 14 days under refrigeration is assigned by USP <795> for preserved aqueous oral preparations, and the preparation is labelled with a shake-well instruction because zinc-loaded liposomes sediment as a loosely packed floc that redisperses with five inversions. The suspended product is tested for dose uniformity by withdrawing five 5 mL aliquots from the top, middle, and bottom of the bottle after 24 hours without shaking; the zinc concentration in each aliquot must remain within 90.0% to 110.0% of label claim to demonstrate sedimentation stability. Zinc assay is performed by USP <730> ICP-OES after dilution with 1% nitric acid, and microbial limits are controlled by USP <61> and USP <62> for nonsterile oral liquids. This liquid format is used when tablet swallowing is not feasible, and the clinical dose is titrated by body weight in pediatric patients; however, the marketing authorization holder must provide a product-specific stability protocol because the interaction between the suspending agent and the liposomal surface may alter zeta potential and accelerate aggregation in some buffer systems.